1 SDI Paper Template Version 1.6 Date 11.10.2012

Kaurenoic acid isolated from the root bark of *Annona senegalensis* induces cytotoxic and antiproliferative effects against PANC-1 and HeLa cells

Theophine C. Okoye[1*], Peter A. Akah[1], Chukwuemeka S. Nworu[1], Adaobi C. Ezike[1]

[1]Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Enugu State, Nigeria.

ABSTRACT (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

Aims: Cancer is one of the leading causes of death worldwide with an estimated 6.7 million deaths and 24.6 million people living with cancer in 2002. Presently, there is a global increase in prevalence, mortality and health burden of various malignancies. World Health Organization (WHO) report projected that cancer prevalence rates could further increase by 50% to 15 million new cases in the year 2020. The bioactivity guided isolation of the bioactive constituent, and its characterization, responsible for the anticonvulsant effects of the root bark extract of *A. senegalensis* yielded kaur-16-en-19-oic acid (KA). Therefore, the aim of this study was to evaluate the anti-proliferative activity of kaurenoic acid from *A. senegalensis* on selected cancer cell lines.
Study design: The study was designed to ascertain the antiproliferative and cytotoxic effects of kaurenoic acid, a terpenoid isolated from the root bark of Nigerian *Annona senegalensis* (Annonaceae).
Place and duration of study: Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria, between October 2010 and June, 2012.
Methodology: Human embryonic kidney cells expressing SV40 Large T-antigen (293 T), Pancreatic tumour (PANC-1) and Henrietta Lacks' cervical (HeLa) cell lines were used in the study using standard MTT, 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide, assay method.
Results: Kaurenoic acid (KA) exhibited cytotoxic effects against the cells with estimated IC_{50} values of 0.93, 0.74 and 0.52 M concentrations for 293 T, HeLa and PANC-1 cells respectively. This is an indication of the possible potentials of KA in the treatment of cervical and pancreatic cancers.
Conclusions: Kaurenoic acid (KA) a terpenoid, possesses antiproliferative effect against HeLa and PANC-1 cell lines, and could be the anticancer constituent in the root bark extract of *A. senegalensis* with potentials as a lead in the chemical synthesis of standard anti cancer agents.

*Tel: +234 803 6684506; E-mail: theokuba@yahoo.com

Keywords: **Kaurenoic acid, Annona senegalensis, antiproliferative and cytotoxic**

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

1. INTRODUCTION

Cancer is one of the leading causes of death worldwide with an estimated 6.7 million deaths and 24.6 million people living with cancer in 2002 [1, 2]. The disease caused about 0.6 million deaths in the United States in 2011 [3]. Globally, there is an obvious increase in prevalence, mortality and health burden of various malignancies. World Health Organization (WHO) report [4], projected that cancer prevalence rates could further increase by 50% to 15 million new cases in the year 2020. In Nigeria, the burden of cancer is enormous and quite on the increase and it has been projected that by 2020, cancer incidence for Nigerian males and females may rise to 90.7/100,000 and 100.9/100,000, respectively, with mortality rates of 72.2 and 76/100,000 for males and females respectively [4]. At the early stage diagnosis and detection, cancer is usually managed by surgery and radiotherapy while advanced cases of cancer could be treated with chemotherapeutic agents. Although chemotherapeutic agents are effective, they are often associated with serious adverse effects and drug resistance [5]. Additionally, the exorbitant costs, non-affordability and unavailability of effective anticancer agents in some parts of world, have paved way for herbal therapies as alternatives in the management of cancer in rural communities. Herbal therapies employing plants extracts and plant bioactive compounds have long been used in the treatment of cancer [6, 7]. The fact that herbs and plant-derived products lack much of the toxicity in the synthetic chemicals enhances their appeal fro treating cancer and for long term preventive strategies [8]. Therefore, other therapeutic options that are devoid of serious adverse effects at the same time cheap and affordable are obviously desired. The use of natural sources can provide an opportunity for the isolation and chemical characterization of phytoconstituents that could be the desired source of lead compounds for the introduction of novel chemotherapeutic agents. Hence the urgent need for novel therapeutic compounds (or leads) with potent anticancer effects and minimal toxicities to normal cellular system. The plant *Annona senegalensis* Pers. (Annonaceae) popularly known as African custard apple or wild custard apple [9], has been reported to possess cytotoxic and anticancer effects [10, 11, 12]. A diterpenoid compound, kaurenoic acid, isolated from the root bark of *A. senegalensis* was reported to possess antimicrobial [13] and anticonvulsant [14] effects. Also from other sources, kaurenoic acid has shown to possess anti-inflammatory [15], anticonvulsant [16] and antimicrobial activities [17]. Among the naturally isolated phytoconstituents used in cancer chemotherapy are the diterpenoid compounds known as the taxanes (paclitaxel and docetaxel), vinca alkaloids (vincristine and vinblastine) and podophyllotoxins (etoposides, teniposides and etopophos) [18]. Therefore, due to the reported ethnomedicinal use of *A. senegalensis* root bark extract cancer treatment [10, 12], we serendipitously evaluated the cytotoxic effects of kaurenoic acid isolated from its root bark using some selected human cancer cell lines.

2. MATERIAL AND METHODS

2.1 Plant material

Fresh roots of *A. senegalensis* were collected from Enugu-Ezike, Enugu State, Nigeria in the month of June and authenticated by Mr. A. O. Ozioko of the International Centre for Ethnomedicine and Drug Development (InterCEDD), Nsukka, Enugu State, Nigeria where a voucher specimen was deposited (specimen number: BDCP/INTERCEDD 64). The root-bark was peeled off, cut into pieces and allowed to dry. The dried root-bark was pulverized into coarse powder. The dried powdered root-bark (2.95 kg) was extracted with a mixture of methanol: methylene chloride (1:1) using Soxhlet extractor to obtain the *Annona senegalensis* root bark extract (MME). This was evaporated using a rotary evaporator at reduced pressure to obtain a yield of 375 g (12.71% w/w).

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

2.2 Isolation and purification of A2

The kaurenoic acid, A2, was isolated from the separation and activity guided fractionation of MME. The detailed methods of isolation and purification of A2 from the root bark extract and fractions of *A. senegalensis* have been documented [13,14].

2.3 Identification and characterization of A2

The purity of A2 was assessed by analytical HPLC using a Dionex P580 HPLC system coupled to a photodiode array detector (UVD340S, Dionex Softron GmbH, Germering, Germany). Detection was at 235, 254, 280 and 340 nm. The separation column (125 × 4 mm; length × internal diameter) was prefilled with Eurospher-10 C18 (Knauer, Germany), and a linear gradient of nanopure water (adjusted to pH 2 by addition of formic acid) and methanol was used as eluent. The molar mass was determined by Liquid Chromatography-Electrospray Ionization Mass Spectroscopy (LC-ESI-MS) using a ThermoFinningan LCQ-Deca mass spectrometer (Germany) connected to an UV detector. Complete structural characterization of the pure crystals of A2 was achieved by 1D (HNMR, 13CNMR, DEPT) and 2D (HHCOSY, HMQC, HMBC) NMR spectroscopy using a Bruker ARX-500 and X-ray crystallography. Spot detection was done with ultra-violet (UV) light at 254 nm and spraying with vanillin sulphuric reagent. The melting point of A2 was also determined using a melting point apparatus (Electrothermal®, Cat. No.: IA 6304, England).

2.4 Cell lines

Human embryonic kidney cells expressing SV40 Large T-antigen (293 T), Pancreatic tumour (PANC-1) cell line and Henrietta Lacks' cervical (HeLa) cancer cell line were propagated in D-10 medium, consisting of Dulbecco's modified Eagle's medium (DMEM) with high glucose, 2 mM $_L$-glutamine and supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin. Tissue culture medium and supplements were purchased from Invitrogen (Karlsruhe, Germany). The cell cultures were maintained in a humidified 5% CO_2 atmosphere at 37℃.

2.5 Cytotoxicity studies

The cytotoxicity assay was performed in parallel to the antiviral screening using the MTT, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide], assay method as previously described [19] on 293T, PANC-1, and HeLa cell lines. In the MTT assay, cells were seeded onto a 96-well plate at a concentration of 10^4 cells/well and a volume of 100 µl per well. Different concentrations of the test extracts (31.5-1000 µg/ml) were added to culture wells in triplicate. Culture medium without any drug was used as the "no-drug" control. After incubation at 37℃ under 5% CO_2 for 2 days, a solution of MTT (3 mg/ml, 50µl per well) was added to each well and further incubated at 37℃ + 5% CO_2 for 4 h to allow formazan formation. Subsequently, the medium was removed and 150 µl of DMSO was used to dissolve the resulting blue formazan crystals in living cells. The optical density was determined at 550 nm using a multi-well microtitre plate reader (Tecan, Austria). Each single value of the triplicates was expressed as percent of the mean of triplicates of the "no-drug" control cultures and the mean and standard deviation of the percent values were calculated for each triplicate. The concentration of 50% cellular toxicity (TC_{50}) of the test extracts was calculated by non-linear regression.

2.6 Statistical analysis

Data were analyzed using One Way Analysis of Variance (ANOVA, SPSS Version 16) and expressed as mean ± SEM and multiple comparisons was done using Dunnet test as *post hoc*. Differences between means were regarded significant at $P < 0.05$.

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

3. RESULTS AND DISCUSSION

3.1 RESULTS

3.1.1 Identification and characterization of A2

The A2 was isolated as a white crystalline compound. The melting point range was estimated to be at 170-172 ℃ and in methanol it ex hibited a UV maximum at 214 nm, which is typical of an unconjugated compound. It had a strong peaks at 303.2 (M + H), 650.2 (2M + 2Na) in the positive mode of LC-ESIMS and a corresponding peak at 301.6 (M - H) in the negative mode, which are consistent with the molar mass of 302. Based on this, and the analysis of ^{1}H and ^{13}C NMR, the molecular formula of AS2 was deduced as $C_{20}H_{30}O_{2}$. The analyses of the HNMR, HHCOSY, C-13 NMR, DEPT, HMQC and HMBC (Table 1) and comparison of data with literature reports [20, 21] established the structure of A2 to be kaur-16-en-19-oic acid (Fig. 5). The absolute configuration as shown was based on the observed HNMR coupling constants, HMBC and X-ray crystallography and comparison with literature report [22, 13, 14].

3.1.2 Cytotoxicity studies

The A2 exhibited cytotoxicity effects against the three cell lines tested (Figs. 1, 2 and 3), with estimated IC_{50} values of 281.85, 223.65, 156.35 µg/ml for 293 T, HeLa and PANC-1 cells respectively (Fig. 4). In molar concentrations, the IC_{50} values of kaurenoic acid against the 293 T, HeLa and PANC-1 cells were estimated to be 0.93, 0.74 and 0.52 M respectively. Hence the antiproliferative activity of A2 against the cells in the order of increasing activity was; 293 T > HeLa cells > PANC-1 cells.

3.2 DISCUSSION

Kaurenoic acid, A2, exhibited cytotoxic activity against the 293 T, HeLa and PANC-1 cancer cell lines treated. It exhibited better cytotoxic and antiproliferative activity against HeLa cells than the PANC-1 cells, an indication of the anticancer effects of this diterpenoid on cervical and pancreatic cancers. On a separate reported work, kaurenoic acid has been identified to possess cytotoxic effects against HeLa cell lines [23]. However, the most potent cytotoxic effect on the PANC-1 cells showed the possible antitumor effect of A2 against cancer of the pancreas. Therefore, A2 could serve as a lead compound in the development of novel anticancer agents. Anticancer effect of kaurenoic acid on breast, leukemia and colon cancer cells has also been documented [24, 25, 26]. In addition to kaurenoic acid, other naturally isolated terpenoid compounds have shown to possess anticancer effects [27]. Similarly, betulinic acid, a triterpenoid, isolated from plants of Cactacea family has shown to possess potent anticancer effect against HeLa cells [28]. Documented studies revealed that terpenoids exhibited antitumor activities by inducing apoptosis in various cancer cells by activating various pro-apoptotic signaling cascades and by the inhibition of metastatic progression and tumor-induced angiogenesis [26]. The molecular mechanisms involved in these activities include the inhibition of various oncogenic and anti-apoptotic signaling pathways and suppression of nuclear translocation of various transcription factors including nuclear factor kappa B (NF-κB) [26]. The anti-inflammatory effects of kaurenoic acid isolated from different sources have variously been reported [29,15]. Kaurenoic acid was shown to significantly inhibit inflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages, inhibit the production of nitric oxide and reduced the secretion of

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

178 prostaglanding E (PGE_2), which are all potent mediators of inflammation [29]. There is the
179 possibility that the mechanism of antiproliferative activity of KA might be likely through
180 modulation of inflammatory mediators. In other reported studies, the mechanism of
181 anticancer effects of kaurenoic acid has been attributed to its inhibition of DNA
182 topoisomerases I and II [24] as well as the stimulation of p53 tumor suppressor gene [25].
183 However, the likely specific mechanism of action of kaurenoic acid against these cancer
184 cells at this stage of the work is not yet elucidated. Hence further work is encouraged to
185 determine the possible anti-cancer mechanism of kaurenoic acid.
186
187
188
189
190



191
192
193 **Fig. 1: The effect of kaurenoic acid on the viability of 293-T cells**

194
195
196
197
198
199
200
201
202

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

203
204
205
206



207
208
209 **Fig. 2: Antiproliferative effect of kaurenoic acid on pancreatic cancer (PANC-1)**
210 **cell line**

211
212
213
214
215
216
217
218
219
220
221
222
223
224

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

225
226
227
228
229



230
231 **Fig. 3: Antiproliferative effect of kaurenoic acid on cervical cancer (HeLa) cell**
232 **line**

233
234
235
236
237
238
239
240
241
242
243
244
245
246
247

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

248
249
250
251



252
253
254 **Fig. 4: A comparison of the effects of kaurenoic acid on the viability of 29T**
255 **cells, PANC-1 cells, and HeLA cells**

256
257
258



259
260
261 **Fig. 5: Chemical structure of Kaur-16-en-19-oic acid**
262

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

263
264 **TABLE 1: NMR spectroscopic data of A2[a]**
265

Position	δH	δc	HMBC
1	Ha 0.82 m Hb 1.54 m	41.48	Ha C-20 Hb C-2, C-3
2	1.42 m (2H)	19.29	1, 3, 4, 10
3	Ha 1.01 m Hb 2.17 m	37.97	1,2,4,5,19
4		43.95	
5	1.07 m	57.26	4, 6, 7, 10, 20
6	Ha 1.62 m Hb 1.84 m	22.03	4, 5, 7, 8, 10
7	Ha 1.44 m Hb 1.54 m	40.90	5, 6, 6, 8, 9, 15
8		44.05	
9	1.05 m	55.29	5,, 8, 10, 11, 14, 15, 20
10		39.85	
11	Ha 1.60 m Hb 1.88 m	18.64	9, 10, 12, 13
12	Ha 1.46 m Hb 1.62 m	33.97	11, 13, 16, 14
13	2.61 bs	43.95	C-8, C-12, C-14, C-16, C-17
14	Ha 1.16 Hb 2.02	39.9	
15	2.06	48.48	C-8, C-9, C-16, C-17
16		156.12	
17	Ha 4.72 s Hb 4.78 s	103.21	
18	1.22 s (3H)	29.18	C-2, C-3, C-4, C-5, C-19
19		184.94	
20	0.93 s (3H)	15.79	C-1, C-5, C-9, C-10

266 [a]Spectra were measured in $CDCl_3$ at 500 (^1H) and 150 (^{13}C) MHz. Assignments were made
267 on the basis of DEPT, ^1H-^1H COSY, HMQC and HMBC experiments. The detailed NMR data
268 are available with the author for correspondence and will be readily supplied on request.
269
270
271
272 ## 4. CONCLUSION
273
274 Kaurenoic acid, a diterpenoid, isolated from the root bark extract of *A. senegalensis* Pers.
275 (Annonaceae) possesses cytotoxicty and anticancer effect against PANC-1 and HeLa
276 human cell lines while the specific mechanism of anticancer activity is a point for further
277 research.
278
279
280 ## 5. ACKNOWLEDGEMENTS
281
282 The authors thankfully appreciate Prof. Dr. Mark Hamann of the Department of
283 Pharmacognosy and Phytochemistry, University of Mississippi, USA, for performing the
284 proton NMR and the X-ray crystallography of A2. We appreciate Dr. FBC Okoye for doing

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

part of the NMR spectral data analysis during his stay in Germany. Part of the financial support was from the Ministry of Education, Science and Technology Post Basic Programme, of the Federal Government of Nigeria for the Innovators of Tomorrow (IOT) Award Grant of the World Bank assisted Step-B project.

COMPETING INTERESTS

The authors declare that there are no conflicts of interest.

AUTHORS' CONTRIBUTIONS

Okoye TC and Akah PA designed, performed the experiment on the isolation of the compound and prepare the manuscript. Nworu CS performed the cytotoxicity studies while Ezike AC contributed in the manuscript preparation. All authors read and approve the final manuscript.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P, Global cancer statistics, 2002, CA Cancer J Clin. 2005; 55:74-108.

2. Ji D, Ye J, Jiang Y, Qian B, Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice, BMC Complementary and Alternative Medicine. 2009;9. doi:10.1186/1472-6882-9-20.

3. Siegel R, Ward E, Brawley O, Jemal A, The impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA Cancer J. Clin. 2011; 61:212-236.

4. World Health Organisation, Global cancer rates could increase by 50% to 15 million by 2020, 2003.

5. Kellof GJ, Perspective on cancer chemoprevention research and drug development**,** Adv. Cancer Res. 2000; 78:199-334.

6. Hartwell JL, Plants used against cancer: a survey. Lawrence, M.A. Quarterman Publications, 1982, pp 438-439.

7. Shoeb M, Anticancer agents from medicinal plants. Bangladesh J Pharmacol. 2000; 1:35-41.

8. Harlev E, Nevo E, Solowey E, Bishayee A, Cancer preventive and curative attributes of plants of the cactaceae family: a review. Planta Med. 2013; 79:713-722.

9. Okoye TC, Akah PA, Ezike AC, Okoye MO, Onyeto CA, Ndukwu F et al. Evaluation of the acute and sub acute toxicity of *Annona senegalensis* root bark extracts. Asian Pacific J. of Tropical Medicine. 2012; 5(4):277-282.

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

336 10. Sahpaz S, Bories CH, Loiseau PM, Cartes D, Hocquemiller R, Laurens A, Cave A,
337 Cytotoxic and antiparasitic activity from Annona senegalensis seeds. Planta Medica. 1994;
338 60:538-540.
339
340 11. Sahpaz S, Carmen Gonzalez M, Hocquemiller R, Zafra-Polo MC, Diego C,
341 Annosenegalin and annogalene: two cytotoxic monotetrahydrofuran acetogenins from
342 Annona senegalensis and Annona cherimolia. Phytochemistry. 1996; 42:103-107.
343
344 12. Abubakar AM, Musa AM, Ahmed A, Hussaini IM. The perception and practice of
345 traditional medicine in the treatment of cancers and inflammations by the Hausa and Fulani
346 tribes of northern Nigeria. J Ethnopharmacol. 2007; 111:625–629.
347
348 13. Okoye TC, Akah PA, Okoli CO, Ezike AC, Omeje EO, Odoh UE. Antimicrobial effects of
349 a lipophilic fraction and kaurenoic acid isolated from the root bark extracts of *Annona*
350 *senegalensis*. Evidence-Based Comp. and Alter. Med. 2012; doi:10.1155/2012/831327.
351
352 14. Okoye TC, Akah PA, Omeje EO, Okoye FBC, Nworu CS. Anticonvulsant effect of
353 kaurenoic acid isolated from the root bark of *Annona senegalensis*. Pharmacology
354 Biochemistry and Behavior. 2013; 109:38-43. Doi: 10.1016/j.pbb.2013.05.001.
355
356 15. Sosa-Sequera MC, Suarez O, Dalo DL. Kaurenoic acid: An *in vivo* experimental study of
357 its anti-inflammatory and antipyretic effects. Indian J Pharmacol. 2010; 42(5):293-296.
358
359 16. Dalo NL, Sosa-Sequera MC, Usubillaga A. On the anticonvulsant activity of kaurenoic
360 acid. Invest Clin. 2007; 48:349-358.
361
362 17. Davino SC, Giesbrecht AM, Roque NF. Antimicrobial activity of kaurenoic acid
363 derivatives substituted on carbon-15, Braz J Med Biol Res. 1989; 22:1127-9.
364
365 18. Alexandrova R, Alexandrov I, Velcheva M, Varadinova T. Phytoproducts and cancer,
366 Experimental pathology and parasitology. 2000; 4:15-26.
367
368 19. Romijn JC, Verkoelen CF, Schroeder FH, Application of the MTT assay to human
369 prostate cancer cell lines in vitro: Establishment of test conditions and assessment of
370 hormones-stimulated growth and drug-induced cytostatic and cytotoxic effects. The Prostate.
371 1988; 12(1): 99-110.
372
373 20. Pacheco AG, de Oliveira PM, Piló-Veloso D, Alcântara AFC, ^{13}C-NMR Data of
374 Diterpenes Isolated from *Aristolochia* Species. Molecules. 2009; 14:1245-1262.
375
376 21. Lee I, Kim HJ, Youn UJ, Min BS, Jung HJ, Yoo JK et al. Absolute Configuration of a
377 Diterpene with an Acyclic 1,2-Diol Moiety and Cytotoxicity of Its Analogues from the Aerial
378 Parts of *Aralia cordata*. Bull. Korean Chem. Soc. 2008; 29:1839-1842.
379
380 22. Bruno-Colmenarez J, De Delgado GD, Peña A, Alarcon L, Usubillaga A, Delgado-
381 Méndez P. Structure of *ent*-15-hydroxy-kaur-16-en-19-oic acid. Avances en Química. 2011;
382 6:16-20.
383
384 23. Cuca LE, Coy ED, Alarcon MA, Fernandez A, Aristizabal FA. Cytotoxic effects of some
385 natural compounds isolated from Lauraceae plants and synthetic derivatives. Biomedica,
386 2011; 31(3):335-43.doi: 10.1590/S0120-41572011000300006.
387

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.

388 24. Costa-Lotufo LV, Cunha GMA, Farias PAM, Viana GSB, Cunha KMA, Pessoa C et al.
389 The cytotoxicity and embryotoxic effects of kaurenoic acid, a diterpene isolated from
390 *Copaifera langsdorffii* Oleo-resin. Toxicon. 2002; 40(8): 1231-1234. doi.org/10.1016/S0041-
391 0101(02)00128-9.
392
393 25. Seo CS, Li G, Kim CH, Lee CS, Jahng Y, Chang HW, Son JK. Cytotoxic and DNA
394 topoisomerase I and II inhibitory constituents from the roots of Aralia cordata. Arch. Pharm.
395 Res. 2007; 30:1404-1409.
396
397 26. Peria FM, Tiezzi DG, Tirapelli DP, Neto FS, Tirapelli CR, Ambrosio S et al. J. Clin. Oncol
398 28(Supp: abstract e13641), 2010, ASCO Annual Meeting.
399
400 27. Kuttan G, Pratheeshkumar P, Manu KM, Kuttan R. Inhibition of tumor progression by
401 naturally occurring terpenoids. Pharmaceutical Biology. 2011; 49(10):995-1007.
402 Doi:10.3109/13880209.2011.559476.
403
404 28. Kinoshita K, Yang Y, Koyama K, Takahashi K, Nishino H. Inhibitory effect of some
405 triterpenes from cacti on Pi-incorporation into phospholipids of HeLa cells promoted by 12-O-
406 tetradecanoylphorbol-13-acetate. Phytomedicine. 1999;6:73–77.
407
408 29. Choi RJ, Shin EM, Jung HA, Choi JS, Kim YS. Inhibitory effects of kaurenoic acid from
409 *Aralia continentalis* on LPS-induced inflammatory response in RAW264.7 macrophages.
410 Phytomedicine. 2011; doi:10.1016/j.phymed.2010.11.010.
411
412
413
414
415
416
417

* Tel.: +xx xx 265xxxxx; fax: +xx aa 462xxxxx.
E-mail address: xyz@abc.com.